FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily

The FDA has approved Atebrioz (Zilurgisertib) for the treatment of Fibrodysplasia Ossificans Progressiva in both adults and pediatric patients aged 12 years and older. The recommended dosage for this medication is 100mg once daily. This approval marks the third treatment option available for this rare condition, potentially impacting the market for INCY's stock.